All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
In this video, Platzbecker reports the promising data, presented at ASH 2020, on the telomerase inhibitor imetelstat.
Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
Editorial theme | Genetic pathogenesis of MDS: Translating molecular advances into better diagnosis and prognosis of CCUS and MDS
The last 30 years of advances in molecular biology and high-throughput techniques have significantly impacted the...
What are novel strategies to treat low-risk MDS?
During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig,...
Subscribe to get the best content related to MDS delivered to your inbox